Sign up
Log in
Plus Therapeutics highlights Phase 1 ReSPECT-LM REYOBIQ data in AANS plenary session
Share
Listen to the news
Plus Therapeutics highlights Phase 1 ReSPECT-LM REYOBIQ data in AANS plenary session
  • Plus Therapeutics highlighted Phase 1 ReSPECT-LM trial results for REYOBIQ in a plenary oral presentation already delivered May 2, 2026 at AANS 2026.
  • Data showed a favorable safety profile, signs of improved survival versus historical outcomes, meaningful anti-tumor activity, supporting continued clinical development in leptomeningeal metastases.
  • Translational findings pointed to emerging immune effects that could support future combination approaches with immunotherapies.
  • Enrollment continues in an ongoing Phase 1 multiple-dose study designed to further characterize safety across defined dosing intervals in patients with leptomeningeal metastases from any solid tumor.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605080730PRIMZONEFULLFEED9715960) on May 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
Terms of Service·Privacy Policy·Data Disclaimer
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved